Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling
Standard
Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling. / Kotsiliti, Elena; Leone, Valentina; Schuehle, Svenja; Govaere, Olivier; Li, Hai; Wolf, Monika J; Horvatic, Helena; Bierwirth, Sandra; Hundertmark, Jana; Inverso, Donato; Zizmare, Laimdota; Sarusi-Portuguez, Avital; Gupta, Revant; O'Connor, Tracy; Giannou, Anastasios D; Shiri, Ahmad Mustafa; Schlesinger, Yehuda; Beccaria, Maria Garcia; Rennert, Charlotte; Pfister, Dominik; Öllinger, Rupert; Gadjalova, Iana; Ramadori, Pierluigi; Rahbari, Mohammad; Rahbari, Nuh; Healy, Marc E; Fernández-Vaquero, Mirian; Yahoo, Neda; Janzen, Jakob; Singh, Indrabahadur; Fan, Chaofan; Liu, Xinyuan; Rau, Monika; Feuchtenberger, Martin; Schwaneck, Eva; Wallace, Sebastian J; Cockell, Simon; Wilson-Kanamori, John; Ramachandran, Prakash; Kho, Celia; Kendall, Timothy J; Leblond, Anne-Laure; Keppler, Selina J; Bielecki, Piotr; Steiger, Katja; Hofmann, Maike; Rippe, Karsten; Zitzelsberger, Horst; Weber, Achim; Malek, Nisar; Luedde, Tom; Vucur, Mihael; Augustin, Hellmut G; Flavell, Richard; Parnas, Oren; Rad, Roland; Pabst, Olivier; Henderson, Neil C; Huber, Samuel; Macpherson, Andrew; Knolle, Percy; Claassen, Manfred; Geier, Andreas; Trautwein, Christoph; Unger, Kristian; Elinav, Eran; Waisman, Ari; Abdullah, Zeinab; Haller, Dirk; Tacke, Frank; Anstee, Quentin M; Heikenwalder, Mathias.
In: J HEPATOL, Vol. 79, No. 2, 08.2023, p. 296-313.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling
AU - Kotsiliti, Elena
AU - Leone, Valentina
AU - Schuehle, Svenja
AU - Govaere, Olivier
AU - Li, Hai
AU - Wolf, Monika J
AU - Horvatic, Helena
AU - Bierwirth, Sandra
AU - Hundertmark, Jana
AU - Inverso, Donato
AU - Zizmare, Laimdota
AU - Sarusi-Portuguez, Avital
AU - Gupta, Revant
AU - O'Connor, Tracy
AU - Giannou, Anastasios D
AU - Shiri, Ahmad Mustafa
AU - Schlesinger, Yehuda
AU - Beccaria, Maria Garcia
AU - Rennert, Charlotte
AU - Pfister, Dominik
AU - Öllinger, Rupert
AU - Gadjalova, Iana
AU - Ramadori, Pierluigi
AU - Rahbari, Mohammad
AU - Rahbari, Nuh
AU - Healy, Marc E
AU - Fernández-Vaquero, Mirian
AU - Yahoo, Neda
AU - Janzen, Jakob
AU - Singh, Indrabahadur
AU - Fan, Chaofan
AU - Liu, Xinyuan
AU - Rau, Monika
AU - Feuchtenberger, Martin
AU - Schwaneck, Eva
AU - Wallace, Sebastian J
AU - Cockell, Simon
AU - Wilson-Kanamori, John
AU - Ramachandran, Prakash
AU - Kho, Celia
AU - Kendall, Timothy J
AU - Leblond, Anne-Laure
AU - Keppler, Selina J
AU - Bielecki, Piotr
AU - Steiger, Katja
AU - Hofmann, Maike
AU - Rippe, Karsten
AU - Zitzelsberger, Horst
AU - Weber, Achim
AU - Malek, Nisar
AU - Luedde, Tom
AU - Vucur, Mihael
AU - Augustin, Hellmut G
AU - Flavell, Richard
AU - Parnas, Oren
AU - Rad, Roland
AU - Pabst, Olivier
AU - Henderson, Neil C
AU - Huber, Samuel
AU - Macpherson, Andrew
AU - Knolle, Percy
AU - Claassen, Manfred
AU - Geier, Andreas
AU - Trautwein, Christoph
AU - Unger, Kristian
AU - Elinav, Eran
AU - Waisman, Ari
AU - Abdullah, Zeinab
AU - Haller, Dirk
AU - Tacke, Frank
AU - Anstee, Quentin M
AU - Heikenwalder, Mathias
N1 - Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
PY - 2023/8
Y1 - 2023/8
N2 - BACKGROUND & AIMS: The progression of non-alcoholic steatohepatitis (NASH) to fibrosis and hepatocellular carcinoma (HCC) is aggravated by auto-aggressive T cells. The gut-liver axis contributes to NASH, but the mechanisms involved and the consequences for NASH-induced fibrosis and liver cancer remain unknown. We investigated the role of gastrointestinal B cells in the development of NASH, fibrosis and NASH-induced HCC.METHODS: C57BL/6J wild-type (WT), B cell-deficient and different immunoglobulin-deficient or transgenic mice were fed distinct NASH-inducing diets or standard chow for 6 or 12 months, whereafter NASH, fibrosis, and NASH-induced HCC were assessed and analysed. Specific pathogen-free/germ-free WT and μMT mice (containing B cells only in the gastrointestinal tract) were fed a choline-deficient high-fat diet, and treated with an anti-CD20 antibody, whereafter NASH and fibrosis were assessed. Tissue biopsy samples from patients with simple steatosis, NASH and cirrhosis were analysed to correlate the secretion of immunoglobulins to clinicopathological features. Flow cytometry, immunohistochemistry and single-cell RNA-sequencing analysis were performed in liver and gastrointestinal tissue to characterise immune cells in mice and humans.RESULTS: Activated intestinal B cells were increased in mouse and human NASH samples and licensed metabolic T-cell activation to induce NASH independently of antigen specificity and gut microbiota. Genetic or therapeutic depletion of systemic or gastrointestinal B cells prevented or reverted NASH and liver fibrosis. IgA secretion was necessary for fibrosis induction by activating CD11b+CCR2+F4/80+CD11c-FCGR1+ hepatic myeloid cells through an IgA-FcR signalling axis. Similarly, patients with NASH had increased numbers of activated intestinal B cells; additionally, we observed a positive correlation between IgA levels and activated FcRg+ hepatic myeloid cells, as well the extent of liver fibrosis.CONCLUSIONS: Intestinal B cells and the IgA-FcR signalling axis represent potential therapeutic targets for the treatment of NASH.IMPACT AND IMPLICATIONS: There is currently no effective treatment for non-alcoholic steatohepatitis (NASH), which is associated with a substantial healthcare burden and is a growing risk factor for hepatocellular carcinoma (HCC). We have previously shown that NASH is an auto-aggressive condition aggravated, amongst others, by T cells. Therefore, we hypothesized that B cells might have a role in disease induction and progression. Our present work highlights that B cells have a dual role in NASH pathogenesis, being implicated in the activation of auto-aggressive T cells and the development of fibrosis via activation of monocyte-derived macrophages by secreted immunoglobulins (e.g., IgA). Furthermore, we show that the absence of B cells prevented HCC development. B cell-intrinsic signalling pathways, secreted immunoglobulins, and interactions of B cells with other immune cells are potential targets for combinatorial NASH therapies against inflammation and fibrosis.
AB - BACKGROUND & AIMS: The progression of non-alcoholic steatohepatitis (NASH) to fibrosis and hepatocellular carcinoma (HCC) is aggravated by auto-aggressive T cells. The gut-liver axis contributes to NASH, but the mechanisms involved and the consequences for NASH-induced fibrosis and liver cancer remain unknown. We investigated the role of gastrointestinal B cells in the development of NASH, fibrosis and NASH-induced HCC.METHODS: C57BL/6J wild-type (WT), B cell-deficient and different immunoglobulin-deficient or transgenic mice were fed distinct NASH-inducing diets or standard chow for 6 or 12 months, whereafter NASH, fibrosis, and NASH-induced HCC were assessed and analysed. Specific pathogen-free/germ-free WT and μMT mice (containing B cells only in the gastrointestinal tract) were fed a choline-deficient high-fat diet, and treated with an anti-CD20 antibody, whereafter NASH and fibrosis were assessed. Tissue biopsy samples from patients with simple steatosis, NASH and cirrhosis were analysed to correlate the secretion of immunoglobulins to clinicopathological features. Flow cytometry, immunohistochemistry and single-cell RNA-sequencing analysis were performed in liver and gastrointestinal tissue to characterise immune cells in mice and humans.RESULTS: Activated intestinal B cells were increased in mouse and human NASH samples and licensed metabolic T-cell activation to induce NASH independently of antigen specificity and gut microbiota. Genetic or therapeutic depletion of systemic or gastrointestinal B cells prevented or reverted NASH and liver fibrosis. IgA secretion was necessary for fibrosis induction by activating CD11b+CCR2+F4/80+CD11c-FCGR1+ hepatic myeloid cells through an IgA-FcR signalling axis. Similarly, patients with NASH had increased numbers of activated intestinal B cells; additionally, we observed a positive correlation between IgA levels and activated FcRg+ hepatic myeloid cells, as well the extent of liver fibrosis.CONCLUSIONS: Intestinal B cells and the IgA-FcR signalling axis represent potential therapeutic targets for the treatment of NASH.IMPACT AND IMPLICATIONS: There is currently no effective treatment for non-alcoholic steatohepatitis (NASH), which is associated with a substantial healthcare burden and is a growing risk factor for hepatocellular carcinoma (HCC). We have previously shown that NASH is an auto-aggressive condition aggravated, amongst others, by T cells. Therefore, we hypothesized that B cells might have a role in disease induction and progression. Our present work highlights that B cells have a dual role in NASH pathogenesis, being implicated in the activation of auto-aggressive T cells and the development of fibrosis via activation of monocyte-derived macrophages by secreted immunoglobulins (e.g., IgA). Furthermore, we show that the absence of B cells prevented HCC development. B cell-intrinsic signalling pathways, secreted immunoglobulins, and interactions of B cells with other immune cells are potential targets for combinatorial NASH therapies against inflammation and fibrosis.
KW - Humans
KW - Mice
KW - Animals
KW - Non-alcoholic Fatty Liver Disease/complications
KW - Carcinoma, Hepatocellular/pathology
KW - Liver Neoplasms/genetics
KW - Mice, Inbred C57BL
KW - Liver/pathology
KW - Fibrosis
KW - Liver Cirrhosis/complications
KW - Mice, Transgenic
KW - Microbiota
KW - Immunoglobulin A/metabolism
KW - Disease Models, Animal
KW - Diet, High-Fat/adverse effects
U2 - 10.1016/j.jhep.2023.04.037
DO - 10.1016/j.jhep.2023.04.037
M3 - SCORING: Journal article
C2 - 37224925
VL - 79
SP - 296
EP - 313
JO - J HEPATOL
JF - J HEPATOL
SN - 0168-8278
IS - 2
ER -